Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of “Hold” from Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have received an average rating of “Hold” from the ten analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $9.33.

Several analysts have weighed in on FULC shares. HC Wainwright reissued a “neutral” rating and issued a $4.00 target price on shares of Fulcrum Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada reissued a “sector perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in FULC. State Street Corp grew its holdings in shares of Fulcrum Therapeutics by 61.4% during the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after buying an additional 638,955 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Fulcrum Therapeutics by 13.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,480,926 shares of the company’s stock worth $9,182,000 after acquiring an additional 176,114 shares during the last quarter. Geode Capital Management LLC grew its stake in Fulcrum Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock worth $4,716,000 after acquiring an additional 13,485 shares during the period. Braidwell LP acquired a new position in Fulcrum Therapeutics in the 3rd quarter valued at $3,817,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Fulcrum Therapeutics by 223.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,185 shares of the company’s stock worth $2,032,000 after purchasing an additional 393,202 shares during the period. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Fulcrum Therapeutics Price Performance

FULC opened at $3.69 on Monday. Fulcrum Therapeutics has a 1-year low of $2.86 and a 1-year high of $13.70. The stock has a market cap of $199.03 million, a P/E ratio of -11.90 and a beta of 2.03. The stock’s 50 day simple moving average is $4.23 and its 200 day simple moving average is $5.14.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.